ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · IEX Real-Time Price · USD
+0.18 (3.01%)
At close: Apr 16, 2024, 4:00 PM
-0.05 (-0.81%)
After-hours: Apr 16, 2024, 7:56 PM EDT

ADMA Biologics Statistics

Total Valuation

ADMA Biologics has a market cap or net worth of $1.41 billion. The enterprise value is $1.49 billion.

Market Cap 1.41B
Enterprise Value 1.49B

Important Dates

The next estimated earnings date is Wednesday, May 8, 2024, after market close.

Earnings Date May 8, 2024
Ex-Dividend Date n/a

Share Statistics

ADMA Biologics has 228.22 million shares outstanding. The number of shares has increased by 13.19% in one year.

Shares Outstanding 228.22M
Shares Change (YoY) +13.19%
Shares Change (QoQ) -3.32%
Owned by Insiders (%) 2.63%
Owned by Institutions (%) 77.45%
Float 223.72M

Valuation Ratios

PE Ratio n/a
Forward PE 19.17
PS Ratio 5.44
Forward PS 4.13
PB Ratio 10.40
P/FCF Ratio 348.93
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 290.26, with an EV/FCF ratio of 368.86.

EV / Earnings n/a
EV / Sales 5.76
EV / EBITDA 290.26
EV / EBIT n/a
EV / FCF 368.86

Financial Position

The company has a current ratio of 5.16, with a Debt / Equity ratio of 0.97.

Current Ratio 5.16
Quick Ratio 1.58
Debt / Equity 0.97
Debt / EBITDA 25.71
Debt / FCF 32.67
Interest Coverage -0.13

Financial Efficiency

Return on equity (ROE) is -19.50%.

Return on Equity (ROE) -19.50%
Return on Assets (ROA) -8.30%
Return on Capital (ROIC) n/a
Revenue Per Employee $413,806
Profits Per Employee -$45,255
Employee Count 624
Asset Turnover 0.76
Inventory Turnover 1.01


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +84.43% in the last 52 weeks. The beta is 0.43, so ADMA Biologics's price volatility has been lower than the market average.

Beta (1Y) 0.43
52-Week Price Change +84.43%
50-Day Moving Average 5.87
200-Day Moving Average 4.44
Relative Strength Index (RSI) 51.09
Average Volume (30 Days) 2,556,219

Short Selling Information

The latest short interest is 7.29 million, so 3.20% of the outstanding shares have been sold short.

Short Interest 7.29M
Short Previous Month 7.99M
Short % of Shares Out 3.20%
Short % of Float 3.26%
Short Ratio (days to cover) 2.09

Income Statement

In the last 12 months, ADMA Biologics had revenue of $258.22 million and -$28.24 million in losses. Loss per share was -$0.13.

Revenue 258.22M
Gross Profit 88.94M
Operating Income 21.63M
Pretax Income -28.24M
Net Income -28.24M
EBIT -3.21M
Loss Per Share -$0.13
Full Income Statement

Balance Sheet

The company has $51.35 million in cash and $131.64 million in debt, giving a net cash position of -$80.29 million or -$0.35 per share.

Cash & Cash Equivalents 51.35M
Total Debt 131.64M
Net Cash -80.29M
Net Cash Per Share -$0.35
Equity / Book Value 135.21M
Book Value Per Share 0.59
Working Capital 207.21M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $8.80 million and capital expenditures -$4.77 million, giving a free cash flow of $4.03 million.

Operating Cash Flow 8.80M
Capital Expenditures -4.77M
Free Cash Flow 4.03M
FCF Per Share $0.02
Full Cash Flow Statement


Gross margin is 34.44%, with operating and profit margins of 8.38% and -10.94%.

Gross Margin 34.44%
Operating Margin 8.38%
Pretax Margin -10.94%
Profit Margin -10.94%
EBITDA Margin 1.98%
EBIT Margin -1.24%
FCF Margin 1.56%

Dividends & Yields

ADMA Biologics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -13.19%
Shareholder Yield -13.19%
Earnings Yield -2.01%
FCF Yield 0.29%

Analyst Forecast

The average price target for ADMA Biologics is $7.88, which is 27.92% higher than the current price. The consensus rating is "Strong Buy".

Price Target $7.88
Price Target Difference 27.92%
Analyst Consensus Strong Buy
Analyst Count 4
Revenue Growth Forecast (5Y) 10.81%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a


ADMA Biologics has an Altman Z-Score of 3.7 and a Piotroski F-Score of 5.

Altman Z-Score 3.7
Piotroski F-Score 5